Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 4
2006 6
2007 6
2008 4
2009 6
2010 11
2011 9
2012 9
2013 13
2014 8
2015 6
2016 13
2017 4
2018 6
2019 12
2020 8
2021 5
2022 10
2023 7
2024 8
2025 16
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis.
Chen Y, Shi N, Lei X, Ren P, Lan L, Chen L, Wang Y, Xu Y, Lin Y, Chen J, Han F. Chen Y, et al. Rheumatology (Oxford). 2025 Jan 1;64(1):221-227. doi: 10.1093/rheumatology/kead674. Rheumatology (Oxford). 2025. PMID: 38145455 Free article.
The pathogenesis of lupus nephritis is characterized by B-cell activation and autoantibody formation. Rituximab and belimumab, as well as telitacicept, target B cells through different mechanisms, potentially exerting a synergistic effect in the treatment of …
The pathogenesis of lupus nephritis is characterized by B-cell activation and autoantibody formation. Rituximab and bel …
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694 Free article.
Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and …
Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered …
Treatment Options for Refractory Lupus Nephritis.
Anders HJ, Hiepe F. Anders HJ, et al. Clin J Am Soc Nephrol. 2019 May 7;14(5):653-655. doi: 10.2215/CJN.03230319. Epub 2019 Apr 12. Clin J Am Soc Nephrol. 2019. PMID: 30979714 Free PMC article. No abstract available.
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF 3rd, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Atisha-Fregoso Y, et al. Arthritis Rheumatol. 2021 Jan;73(1):121-131. doi: 10.1002/art.41466. Epub 2020 Dec 1. Arthritis Rheumatol. 2021. PMID: 32755035 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN). METHODS: In a multicenter, randomized, open-label clinical trial, 43 patients with re …
OBJECTIVE: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of …
Refractory lupus nephritis: When, why and how to treat.
Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Kronbichler A, et al. Autoimmun Rev. 2019 May;18(5):510-518. doi: 10.1016/j.autrev.2019.03.004. Epub 2019 Mar 4. Autoimmun Rev. 2019. PMID: 30844548 Review.
Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persisting or worsening disease activity despite therapy, but the definition is complicated by the parameters of response, proteinuria and renal f …
Refractory lupus nephritis indicates an inadequate response to lupus nephritis therapy. It implies persis …
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT. Fanouriakis A, et al. Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29. Ann Rheum Dis. 2019. PMID: 30926722 Free article.
Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. ... …
Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic mainte …
Experience with abatacept in refractory lupus nephritis.
Calatayud E, Montomoli M, Ávila A, Sancho Calabuig A, Alegre-Sancho JJ. Calatayud E, et al. Rheumatol Int. 2023 Dec;43(12):2319-2326. doi: 10.1007/s00296-023-05389-0. Epub 2023 Aug 31. Rheumatol Int. 2023. PMID: 37650922 Free PMC article. Review.
Lupus nephritis is a major cause of morbidity in patients with systemic lupus erythematosus. ...Based on our experience, abatacept should be considered as a safe rescue therapy in patients with refractory lupus nephritis and proteinuria w …
Lupus nephritis is a major cause of morbidity in patients with systemic lupus erythematosus. ...Based on our experience …
Single-dose rituximab in refractory lupus nephritis.
Kotagiri P, Martin A, Hughes P, Becker G, Nicholls K. Kotagiri P, et al. Intern Med J. 2016 Aug;46(8):899-901. doi: 10.1111/imj.13136. Intern Med J. 2016. PMID: 27242250
AIM: To investigate the response to single-dose rituximab, added to standard corticosteroids plus additional immunosuppressive agent, in refractory lupus nephritis. ...Side-effects were minimal. CONCLUSIONS: Single-dose rituximab is effective in …
AIM: To investigate the response to single-dose rituximab, added to standard corticosteroids plus additional immunosuppressive agent, …
157 results